Strand V, et al. - Authors evaluated the impact of abatacept treatment on patient-reported outcomes (PROs) in psoriatic arthritis (PsA). They randomized (1:1) patients with PsA to subcutaneous abatacept 125 mg weekly/placebo for 24 weeks with early escape (EE) to open-label abatacept (week 16). PROs were improved in patients with PsA with abatacept treatment vs placebo, with better results in elevated baseline CRP and TNFi-naïve subpopulations. They noted numerically greater PRO improvements in patients with baseline CRP > ULN vs CRP ≤ ULN at week 16.